MK 8325

Drug Profile

MK 8325

Alternative Names: MK-8325

Latest Information Update: 11 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 08 Aug 2013 Merck & Co. terminates a phase I trial in Hepatitis C in Belgium and Germany (NCT01554189)
  • 01 Mar 2013 Merck & Co. suspends enrolment into its phase I trial in Hepatitis C in Belgium and Germany (NCT01554189)
  • 30 Apr 2012 Phase-I clinical trials in Hepatitis C in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top